Connect with us

Coronavirus Outbreak

Bharat Biotech Inks Licensing Deal With Washington University School Of Medicine To Advance COVID-19 Intranasal Vaccine Technology

According to the Chairman of Bharat Biotech, the Phase I trials of the intranasal vaccine for COVID-19 will take place in Saint Louis University’s Vaccine and Treatment Evaluation Unit in USA

Bharat Biotech Inks Licensing Deal With Washington University School of Medicine To Advance COVID-19 Intranasal Vaccine Technology
Highlights
  • Intranasal vaccine does not need needles and syringes: Dr. Ella
  • Bharat Biotech is also developing COVAXIN which is in Phase 2 trials
  • A nasal vaccine can be useful in controlling COVID-19 spread: Expert

Hyderabad: Vaccine Innovator, Bharat Biotech on Wednesday announced, a licensing agreement with Washington University School of Medicine (WUSM) in St. Louis for a novel chimp-adenovirus, single dose intranasal vaccine for COVID-19. With this, Bharat Biotech owns the right to distribute the vaccine in all markets except the USA, Japan and Europe. The Phase I trials will take place in Saint Louis University’s Vaccine and Treatment Evaluation Unit. While Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India. The company will undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad.

Also Read: Coronavirus Explainer: What Is COVAX Initiative?

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive.”

Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world, Dr Ella stated.

Dr David T Curiel, MD, Ph.D., Director of Biologic Therapeutics Center and Professor of Radiation Oncology at Washington University School of Medicine in St. Louis and Precision Virologics Interim CEO said,

The ability to accomplish effective immunisation with a single nasal dose is a major advantage, offering broader reach and easier administration. An effective nasal dose not only protects against COVID-19, but it also prevents the spread of the disease by offering another kind of immunity that occurs primarily in the cells that line the nose and throat. Most other vaccine candidates currently under development cannot do that.

This vaccine expands Bharat’s portfolio of vaccines that are currently being developed and are in various stages of clinical development including COVAXIN which is currently in Phase II human clinical trials in India.

Also Read: 30 COVID-19 Vaccine Candidates Under Development: Union Minister Harsh Vardhan

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

World

26,27,61,966Cases
22,35,18,265Active
3,40,28,506Recovered
52,15,195Deaths
Coronavirus has spread to 196 countries. The total confirmed cases worldwide are 26,27,61,966 and 52,15,195 have died; 22,35,18,265 are active cases and 3,40,28,506 have recovered as on December 1, 2021 at 3:56 am.

India

3,45,96,776 8,954Cases
99,0231,520Active
3,40,28,506 10,207Recovered
4,69,247 267Deaths
In India, there are 3,45,96,776 confirmed cases including 4,69,247 deaths. The number of active cases is 99,023 and 3,40,28,506 have recovered as on December 1, 2021 at 2:30 am.

State Details

State Cases Active Recovered Deaths
Maharashtra

66,35,658 678

11,226 299

64,83,435 942

1,40,997 35

Kerala

51,41,814 4,723

44,314 824

50,57,368 5,370

40,132 177

Karnataka

29,96,148 291

6,445 462

29,51,492 745

38,211 8

Tamil Nadu

27,26,917 720

8,244 47

26,82,192 758

36,481 9

Andhra Pradesh

20,72,909 184

2,149 47

20,56,318 134

14,442 3

Uttar Pradesh

17,10,399 12

89 3

16,87,399 8

22,911 1

West Bengal

16,16,083 705

7,731 2

15,88,866 694

19,486 13

Delhi

14,40,934 34

287 2

14,15,549 32

25,098

Odisha

10,49,108 228

2,188 23

10,38,509 203

8,411 2

Chhattisgarh

10,06,813 34

318 0

9,92,902 34

13,593

Rajasthan

9,54,785 15

193 6

9,45,637 9

8,955

Gujarat

8,27,475 40

275 13

8,17,108 27

10,092

Madhya Pradesh

7,93,170 20

119 7

7,82,523 27

10,528

Haryana

7,71,709 17

163 2

7,61,492 19

10,054

Bihar

7,26,223 4

36 3

7,16,524 7

9,663

Telangana

6,75,994 196

3,591 10

6,68,411 184

3,992 2

Assam

6,16,852 144

2,625 30

6,08,124 109

6,103 5

Punjab

6,03,279 21

325 4

5,86,352 22

16,602 3

Jharkhand

3,49,244 12

98 3

3,44,006 9

5,140

Uttarakhand

3,44,255 28

141 9

3,36,706 19

7,408

Jammu And Kashmir

3,36,852 171

1,625 1

3,30,751 172

4,476

Himachal Pradesh

2,27,195 102

834 10

2,22,513 91

3,848 1

Goa

1,78,928 38

284 8

1,75,260 30

3,384

Mizoram

1,35,175 365

3,751 54

1,30,927 415

497 4

Puducherry

1,28,924 31

284 12

1,26,768 43

1,872

Manipur

1,25,205 36

649 6

1,22,579 40

1,977 2

Tripura

84,805 14

81 3

83,900 10

824 1

Meghalaya

84,480 19

294 9

82,713 9

1,473 1

Chandigarh

65,465 9

65 7

64,580 2

820

Arunachal Pradesh

55,276 3

35 0

54,961 3

280

Sikkim

32,242 9

124 3

31,715 6

403

Nagaland

32,122 13

133 7

31,293 20

696

Ladakh

21,578 38

276 26

21,088 12

214

Dadra And Nagar Haveli

10,683

1 0

10,678

4

Lakshadweep

10,394

24 0

10,319

51

Andaman And Nicobar Islands

7,683

6 2

7,548 2

129

Coronavirus Outbreak: Full CoverageTesting CentresFAQs

Highlights From The 12-Hour Telethon

Leaving No One Behind

Mental Health

Environment

Join Us